Validation of stem cell markers in clinical prostate cancer: α6-Integrin is predictive for non-aggressive disease
The Prostate2013Vol. 74(5), pp. 488–496
Citations Over TimeTop 10% of 2013 papers
A. Marije Hoogland, Esther I. Verhoef, Monique J. Roobol, Fritz H. Schröder, Mark F. Wildhagen, Theodorus van der Kwast, Guido Jenster, Geert J.L.H. van Leenders
Abstract
Expression of α2-integrin and EZH2 in a small fraction of prostate cancer cells is supportive for their role as stem cell marker. Although α6-integrin was not a unique stem cell marker, it was predictive for prostate cancer biochemical and local recurrence, and disease specific death. The validity of CD117, CD133, and OCT3/4 as prostate cancer stem cell marker is questionable since these proteins were not expressed in clinical prostate cancer.
Related Papers
- → Cancer Stem Cell Traits in Tumor Spheres Derived from Primary Laryngeal Carcinoma Cell Lines(2021)25 cited
- → The ALDH1+ subpopulation of the human NMFH-1 cell line exhibits cancer stem-like characteristics(2015)17 cited
- → Expression Compilation of Several Putative Cancer Stem Cell Markers by Primary Ovarian Carcinoma(2010)8 cited
- → Characterization of sphere-forming cells with stem-like properties from the gastric cancer cell lines MKN45 and SGC7901(2014)7 cited
- → Abstract LB-113: Non-small cell lung cancer cells with high ALDH1 activity display cancer stem cell properties and show chemoresistance(2011)